Testing a Prediction Model to Guide Kidney Cancer Treatment Choices
Uses past records of 4700 kidney cancer patients to test a risk prediction model.
Plain-language title generated from the registry record
Registry title: Validation of RCC Predicting Model With Emulated-target Trial
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with kidney cancer (renal cell carcinoma) who had surgery to remove the tumor or the kidney.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Primary renal cell carcinoma, diagnosed before and during surgery. This includes people with a tumor clot in a vein.
- Earlier treatment
- Must have had radical nephrectomy or nephron-sparing surgery (kidney surgery).
Main reasons for not taking part
- Seriously missing clinical information
- History of other cancers
- Cancer came back before the first check-up after surgery
- Stopped adjuvant (after-surgery) treatment within the first two courses because of severe side effects
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07117227, who can take part
Where in China
- Peking University Third HospitalBeijing, ChinaContact: Jiyuan Chen, masterTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT07117227
- Record updated
- 14 April 2026
- Original description
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .Read full original descriptionShow less
Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
Inclusion: Adults ≥18 years of age; Diagnosis of primary renal cell carcinoma before and during the surgery; Received radical nephrectomy/nephron-sparing surgery.
Exclusion: History of other malignant tumors; Subjects with severely missing clinical information; Recurrence observed before first postoperative follow-up; Discontinue the adjuvant treatment within in the first two course because of severe adverse react.